Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CONTROL: adalimumab introduction versus methotrexate dose escalation in psoriatic arthritis
2016-000191-21Phase 4Completed
- Sponsor
- AbbVie Inc.
- Start
- Nov 2016
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial in psoriatic arthritis (PsA) comparing Adalimumab introduced plus methotrexate 15 mg weekly with Methotrexate dose escalation alone (2 arms). Primary endpoint: Proportion achieving minimal disease activity at Week 16. Started Nov 2016; status: completed.
02
Drugs
adalimumabmethotrexate
03
Conditions
psoriatic arthritis (PsA)
Beyond the preview
Go deeper on 2016-000191-21.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-000191-21.